Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates.
The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive \u00a386.6m over the next five years to fund 15 research themes.
Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.
On Tuesday 13th September, the Oxford early cancer detection community gathered at Worcester College to discuss the latest developments in this field, sparking ideas and collaborations for future research.
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin\u2019s mechanism of action when taken as a preventative for mTP53-driven cancers.
The National Cancer Imaging Translational Accelerator (NCITA) in partnership with the ReIMAGINE Consortium have announced the release of a unique clinical imaging dataset from the Prostate MRI Imaging Study (PROMIS)).
Congratulations to Joshua Bull, Felix Jackson, Eoghan Mulholland and Lauren Murphy who have been awarded OxCODE funds to attend this year\u2019s Early Detection of Cancer conference in Oregon.
Dr Francesco Boccellato wins a CRUK Early Detection and Diagnosis primer award to study tissue shape changes in the pre-cancerous stomach conditions, atrophic gastritis and intestinal metaplasia
The AI-REAL programme led by Professor Anna Schuh and research teams in Tanzania and Uganda is improving the early detection and outcomes of childhood lymphoma in the region by increasing the speed and precision of diagnosis.
Substantial disagreement in individual risk prediction was found between different polygenic risk scores for breast cancer, hypertension and dementia using genotyping data from the UK Biobank.
The joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) provides a clear strategy for the use of FIT in the colorectal cancer diagnostic pathway.
Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.
Congratulations to Sarah Blagden, Skirmantas Kriaucionis and their collaborators who have been awarded funding in the third round of the OxCODE Funding Scheme.
On Wednesday 8th June 2022, the DeLIVER consortium gathered for the first time to hear about the team\u2019s progress towards the aim of detecting liver cancer earlier.
![\"A](\"https://www.oxcode.ox.ac.uk/news/assessing-a-combined-approach-for-risk-stratified-population-screening-for-colorectal-cancer/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n